Brief: Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
14/05/2024 12:57
May 14 (Reuters) - Kura Oncology Inc KURA.O :
* KURA ONCOLOGY INC: COMPLETES ENROLLMENT IN
REGISTRATION-DIRECTED
TRIAL OF ZIFTOMENIB IN NPM1-MUTANT AML
* KURA ONCOLOGY INC: TOPLINE DATA EXPECTED IN EARLY 2025
Source text for Eikon: ID:nGNX5b9YQS
Further company coverage: KURA.O
((Reuters.Briefs@thomsonreuters.com;))